HMGB1 as a DNA-binding cytokine.

Area of Science:

• Molecular Biology
• Immunology
• Cell Biology

Background:

• High mobility group box chromosomal protein 1 (HMGB1) is a conserved nuclear protein involved in DNA architecture and gene transcription.
• Extracellular HMGB1 functions as a late-acting inflammatory mediator, signaling through the receptor for advanced glycation end-products.
• HMGB1 is released by necrotic cells and actively secreted by macrophages, promoting inflammation and cytokine production.

Purpose of the Study:

• To investigate the role of HMGB1 as a proinflammatory mediator.
• To explore the therapeutic potential of targeting HMGB1, specifically its A box domain, in inflammatory diseases.

Main Methods:

• Analysis of HMGB1's role in inflammatory responses, including its passive release by necrotic cells and active secretion by macrophages.
• Structural analysis of HMGB1 domains (A box, B box, C terminus).
• Administration of recombinant HMGB1 A box protein and anti-HMGB1 antibodies in mouse models of lethal sepsis.

Main Results:

• HMGB1 is a critical mediator of systemic inflammation, endotoxin lethality, acute lung injury, arthritis, and macrophage activation.
• The B box domain of HMGB1 mediates its proinflammatory function, while the A box domain exhibits antagonistic, anti-inflammatory effects.
• Treatment with HMGB1 A box protein or neutralizing antibodies successfully rescued mice from lethal sepsis, even with delayed administration, indicating a wide therapeutic window.

Conclusions:

• HMGB1 is a key driver of inflammatory pathogenesis and a potential therapeutic target.
• The HMGB1 A box domain possesses significant anti-inflammatory properties with therapeutic potential.
• Targeting HMGB1 offers a promising strategy for treating severe inflammatory conditions like sepsis.